The order this company entered each market — oldest to newest
GC Pharma applies for Hunterase ICV approval in Peru
GC Green Cross presents immunoglobulin thrombosis research at ISTH 2025
Sign up to see the full signal feed
How 녹십자홀딩스's international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
녹십자홀딩스You | 0 | 0 | 0% | 0 | 12 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No tracked technology yet
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
US excludes pharmaceuticals from reciprocal tariffs on South Korea. Korean pharma stocks rise slightly. Separate drug tariffs still possible in future.
GC Green Cross's Hunter syndrome treatment 'Hunterase' showed significant improvement in patient mobility and organ function in Phase 3 clinical trials, as published in 'Genetics in Medicine'.
GC Green Cross presented research on immunoglobulin viscosity at ISTH 2025, suggesting room temperature administration may reduce thrombosis risk. The study compared viscosity of five products across temperatures.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about 녹십자홀딩스's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.